Drug intelligence / Profile preview

shengxue granule

Development stage: Unknown
Lead developer: Hebei Shengxue Dacheng
Administration: Oral

Overview

Shengxue Granule (升血颗粒) is a proprietary Traditional Chinese Medicine (TCM) developed and marketed by Shandong Wohua Pharmaceutical. It is formulated as an oral granule and is primarily indicated for the treatment of anemia and blood deficiency syndromes. The medication is designed to nourish blood and tonify qi, leveraging a combination of herbal ingredients to stimulate hematopoietic function and improve clinical symptoms associated with low red blood cell counts or poor blood quality. As a TCM product, its therapeutic effects are attributed to the synergistic action of multiple natural compounds rather than a single molecular target, aiming to restore physiological balance and support the body's natural blood production processes.

Brand names: Shengxue Granule
Other names: 升血颗粒Shengxue Keli

Beyond the preview

Go deeper on shengxue granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on shengxue granule.

Explore the full profile